Evaluating the impact of mandatory indications on antibiotic utilization in a community hospital

April J. Chan PharmD1, Rosane Nisenbaum PhD2,3,4, Mark Downing MD1,2 and Bradley J. Langford PharmD5,6

1Unity Health Toronto, Ontario, Canada, 2University of Toronto, Ontario, Canada, 3Li Ka Shing Knowledge Institute, Ontario, Canada, 4Applied Health Research Centre and MAP Centre for Urban Solutions, Ontario, Canada, 5Public Health Ontario, Ontario, Canada and 6Hotel Dieu Shaver Health and Rehabilitation Centre, Ontario, Canada

Abstract

Objective: We evaluated the impact of introducing a mandatory indication field into electronic order entry for targeted antibiotics in adult inpatients.

Design: Retrospective, before-and-after trial.

Setting: A 400-bed community hospital.

Interventions: All adult electronic intravenous (IV) and enteral orders for targeted antibiotics (moxifloxacin, ciprofloxacin, clindamycin, vancomycin, and metronidazole) had a mandatory indication field added. Control antibiotics (amoxicillin-clavulanate, ceftriaxone and piperacillin-tazobactam) were chosen to track shifts in antibiotic prescribing due to the introduction of mandatory indication field.

Methods: Descriptive statistics were used to summarize the primary outcome, measured in Defined Daily Doses (DDD) per 1000 patient days (PD). Interrupted time-series (ITS) analysis was performed to compare levels and trends in antibiotic usage of targeted and control antibiotics during 24 months before and after the intervention. Additionally, a descriptive analysis of mandatory indication fields for targeted antibiotics in the postintervention period was conducted.

Results: In total, 4,572 study antibiotic orders were evaluated after the intervention. Preset mandatory indications were selected for 30%–55% of orders. There was decreased usage of targeted antibiotics (mean, 92.02 vs 72.07 DDD/1000-PD) with increased usage of control antibiotics (mean, 102.73 vs 119.91 DDD/1000-PD). ITS analysis showed no statistically significant difference in overall antibiotic usage before and after the intervention for all targeted antibiotics.

Conclusion: This study showed moderate use of preset mandatory indications, suggesting that the preset list of indications can be optimized. There was no impact on overall antibiotic usage with the use of mandatory indications. More prospective research is needed to study the utility of this intervention in different contexts.

(Received 16 February 2022; accepted 8 June 2022)
| Variable | Administration Method |
|----------|-----------------------|
| **CIPROFLOXACIN** | PO IV* |
| Predefined indications, no. of orders | 219 155 |
| Deep-seated or bacteremic gram-negative infection | 36 18 |
| Gram-negative infection and allergy to narrower-spectrum antibiotics | 51 38 |
| Gram-Negative infection resistant to narrower-spectrum antibiotics | 77 59 |
| Suspected or documented *Pseudomonas* infection | 55 40 |
| Free-text field, no. of orders | 415 161 |
| Specified infection | 245 124 |
| UTI/pyelonephritis | 128 9 |
| Intra-abdominal/GI | 53 70 |
| **CLINDAMYCIN** | PO IV* |
| Predefined indications, no. of orders | 15 121 |
| Adjunctive treatment of group A *Streptococcus* infection | 1 22 |
| Obligate (gut) anaerobe (consider metronidazole) | 1 6 |
| Oral anaerobe infection (not advised, consider B-lactam) | 3 7 |
| Surgical infection prevention, severe B-lactam allergy | 10 86 |
| Free-text field, no. of orders | 36 179 |
| Specified infection | 20 92 |
| SSTI/OM | 9 ... |
| GU | ... 40 |
| **METRONIDAZOLE** | PO IV* |
| Predefined indications (no. of orders) | 257 416 |
| Anaerobic infection | 160 384 |
| CDI | 94 28 |
| CNS infection | 1 4 |
| Parasitic infection | 2 0 |
| Free text field (no. of orders) | 268 479 |
| Specified infection | 133 419 |
| Intra-abdominal | 68 278 |
| GI | ... 51 |
| **MOXIFLOXACIN** | PO IV* |
| Predefined indications (no. of orders) | 147 63 |
| Respiratory infection and severe B-lactam allergy | 69 26 |
| Respiratory infection and recent use of B-lactam | 60 25 |
| Other infection (eg, skin) and severe B-lactam allergy | 18 12 |
| Free text field (no. of orders) | 208 118 |
| Specified infection | 159 98 |
| Respiratory | 138 92 |
| **VANCOMYCIN** | PO Enteral |
| Predefined indications (number of orders) | 171 |
| Recurrent CDI | 102 |
| Severe CDI | 58 |
| First episode of mild-to-moderate CDI (not advised) | 11 |
| Free text field, no. of orders | 142 |
| Specified infection (eg, CDI, CDI taper) | 89 |

(Continued)
optimization and education. Staffing consisted of a lead ASP physician and 2 full-time equivalent ASP-trained pharmacists during the study period of October 1, 2013, to October 31, 2017.

All adult electronic intravenous (IV) and enteral orders for targeted antibiotics (ceftriaxone, ciprofloxacin, clindamycin, vancomycin, and metronidazole) had a mandatory indication field added on October 22, 2015. The first three antibiotics (ceftriaxone, ciprofloxacin, clindamycin) were selected based on risk for inappropriate use. The latter two antibiotics (metronidazole and vancomycin) were selected as they had more clear-cut indications to the primary outcome. We used the regression model proposed by Wagner et al.\(^8\) We used Stata version 15 software (StataCorp, College Station, TX) for these analyses. ITS analysis was used to estimate regression parameters by ordinary least-squares regression-based models which accommodated ITS data. These models estimate ordinary least-squares regression coefficients with Newey-West standard errors, which handle autocorrelation and heteroscedasticity. The command “actest” was used to perform the Cumby-Huizinga tests for autocorrelation and the specific lag order up to 12.

This study was approved by the research ethics board at St. Joseph’s Health Centre on January 20, 2017.

**Results**

In total, 8,399 orders were evaluated in the 1-year postintervention period, of which 4,572 orders were for targeted antibiotics and 3,827 were for control antibiotics. The preset mandatory indications were selected 30%–55% of the time, depending on targeted antibiotic (Table 1). When the free-form field was selected, the most common indication noted was a specific infection (eg, urinary tract infection-pyelonephritis for ciprofloxacin oral and intra-abdominal-gastrointestinal for ciprofloxacin IV) with very few indications that were incomprehensible (0–4 instances for each study antibiotic with examples such as a dot and a comma).

After mandatory indication field was introduced, there was decreased usage of targeted antibiotics (mean, 92.02 vs 72.07 DDD/1000-PD), driven by decreased usage of metronidazole (mean, 24.76 vs 18.44 DDD/1000-PD), ciprofloxacin (mean, 27.68 vs 21.30 DDD/1000-PD) and moxifloxacin (mean, 17.70 vs 11.89 DDD/1000-PD). We noted increased usage of control antibiotics (mean, 37.31 vs 43.14 DDD/1000-PD), driven by decreased usage of targeted antibiotics (mean, 92.02 vs 72.07 DDD/1000-PD), driven by decreased usage of metronidazole (mean, 24.76 vs 18.44 DDD/1000-PD), ciprofloxacin (mean, 27.68 vs 21.30 DDD/1000-PD) and moxifloxacin (mean, 17.70 vs 11.89 DDD/1000-PD). We noted increased usage of control antibiotics (mean, 37.31 vs 43.14 DDD/1000-PD) and ceftriaxone (mean, 37.50 vs 46.88 DDD/1000-PD).

The ITS analysis showed levels were not different before and after the intervention for targeted antibiotics with mandatory indications. The difference in antibiotic usage (DDD/1000-PD) before the intervention (83.58; 95% CI, 77.21–89.95) and after the

### Table 1. (Continued)

| Variable                                                                 | Administration Method |
|--------------------------------------------------------------------------|-----------------------|
| **VANCOMYCIN**                                                           | IV                    |
| Predefined indications, no. of orders                                    | 452                   |
| B-lactam resistant gram-positive infection                               | 309                   |
| B-lactam sensitive gram-positive infection, severe B-lactam allergy      | 82                    |
| Surgical infection prevention, severe B-lactam allergy                   | 61                    |
| Single positive blood culture of gram-positive organism when other recent cultures are negative (not recommended) | 0                     |
| **Free-text field, no. of orders**                                       |                       |
| Specified infection                                                      | 378                   |
| SSTI/bone                                                               | 87                    |
| Sepsis                                                                  | 73                    |
| Bacteremia                                                              | 67                    |
| CNS                                                                     | 43                    |
| Culture results/pathogen (eg, GPC in blood, MRSA, Enterococcus, CNST)   | 119                   |

Note. CDI, *Clostridioides difficile* infection; CNS, central nervous system; CNST, coagulase-negative Staphylococci; GI, gastrointestinal; GPC, gram-positive cocci; GU, genitourinary; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; NPO, nothing by mouth; OM, osteomyelitis; SSTI, skin and soft-tissue infection.

*Additional criterion of NPO in preset list of indications.
intervention (80.07; 95% CI, 70.62–89.51) was 3.51 (95% CI, −7.88 to 14.90; \( P = .538 \)). Similarly, the preintervention slope (−0.92 per month) was not different from the postintervention slope (−1.00 per month) (change, −0.08; \( P = .821 \)) (Table 2 and Fig. 1). Considering ITS analysis for individual targeted antibiotics, moxifloxacin levels were significantly different before and after the intervention. The difference between the postintervention level (16.98; 95% CI, 14.25–19.72) and the preintervention level (11.96; 95% CI, 9.00–14.93) was 5.02 (95% CI, 1.10–8.94; \( P = .013 \)). There was no significant change in levels or slopes for other targeted antibiotics. Similarly, ITS analysis for control antibiotics showed that levels were not different before and after the intervention. The difference between the postintervention level (110.85; 95% CI, 101.03–120.66) and the preintervention level (102.25; 95% CI, 94.74–109.76) was 8.60 (95% CI, −3.76 to 20.95; \( P = .168 \)). However, the preintervention slope (−0.04 per month) was different from postintervention slope (0.79 per month; change, 0.82; \( P = .051 \)). Nonetheless, given the small change in DDD/1000-PD, this is likely not clinically significant (Table 3 and Fig. 2). This trend toward increased control antibiotic prescribing was driven by a significant level change seen with piperacillin-tazobactam. The difference between the postintervention level (30.03; 95% CI, 26.67–33.38) and the preintervention level (24.41; 95% CI, 21.61–27.21) was 5.62 (95% CI, 1.25–9.99; \( P = .013 \)).

**Discussion**

Although the use of prescriber-entered indications to track antibiotic prescribing has been described in literature and has been shown to improve appropriate antibiotic prescribing,4–7 our institution is

| Antibiotic            | Rate of Change (Pre-Intervention) DDD/1000-PD/month | Rate of Change (Post-Intervention) DDD/1000-PD/month | Post minus Pre-Intervention Slope Change | \( P \) |
|-----------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------|--------|
| Targeted Antibiotics  | −0.92                                               | −1.00                                               | −0.08                                   | 0.821  |
| Clindamycin           | −0.19                                               | 0.04                                                | 0.23                                    | <0.001 |
| Ciprofloxacin         | −0.03                                               | 0.44                                                | −0.42                                   | 0.052  |
| Moxifloxacin          | −0.44                                               | −0.44                                               | −0.002                                  | 0.992  |
| Metronidazole         | −0.27                                               | −0.19                                               | 0.08                                    | 0.536  |
| Vancomycin            | 0.01                                                | 0.03                                                | 0.02                                    | 0.848  |
| Control Antibiotics   | −0.04                                               | 0.79                                                | 0.82                                    | 0.051  |
| Amoxicillin-clavulanate| −0.15                                               | 0.30                                                | 0.45                                    | 0.061  |
| Ceftriaxone           | 0.38                                                | 0.50                                                | 0.12                                    | 0.610  |
| Piperacillin-tazobactam| −0.27                                               | −0.01                                               | 0.26                                    | 0.140  |

Fig. 1. Mandatory indication antibiotic utilization pre and postintervention.
one of few hospitals in Canada that have adopted mandatory indications in practice. To our knowledge, this is the first study to evaluate the impact of prescriber-selected indications on antibiotic usage of targeted antibiotics and potential shifts in prescribing. The introduction of mandatory fields led to moderate uptake of the predefined indications. Additionally, the use of mandatory indications did not have any significant impact to overall targeted and control antibiotic prescribing. We hypothesized that in the context of an already established ASP and concurrent other ASP interventions such as electronic order sets on common infections and high-intensity prospective audit and feedback, the true impact of mandatory indications may have been diminished. At our institution, ciprofloxacin is listed as 3rd line option for urinary tract infection and is not listed as an option for intra-abdominal infections. High-intensity prospective audit and feedback (PAF) at our institution comprise of twice weekly interdisciplinary rounds on our four internal medicine wards with a review of all internal medicine patients receiving any antimicrobial agent. High-intensity PAF was associated with a reduction in antibiotic use compared to our previous low-intensity PAF which consisted of ad-hoc review of patients on targeted antimicrobials. The antibiotic usage reduction from high-intensity PAF would have some overlap with the reduction in targeted antibiotics seen with mandatory indications. Additionally, perhaps more time was needed to see the impact of this intervention, given we saw more changes in trends than levels.

This study had several limitations. Given its retrospective design, unaccounted confounding factors may have mitigated the change in antibiotic usage. However, our time-series analysis accounted for seasonal and secular (consistent) trends in antibiotic use to reduce the impact of any confounder. Secondly, we did not

| Antibiotic | Targeted Antibiotics | Clindamycin | Ciprofloxacin | Moxifloxacin | Metronidazole | Vancomycin | Control Antibiotics | Amoxicillin-clavulanate | Ceftriaxone | Piperacillin-tazobactam |
|------------|----------------------|-------------|---------------|-------------|--------------|------------|--------------------|------------------------|-------------|------------------------|
|            | Pre-Intervention | Post-Intervention | Post minus Pre-Intervention | P            | Pre-Intervention | Post-Intervention | Post minus Pre-Intervention | Pre-Intervention | Post-Intervention | Pre-Intervention |
| DDD/1000-PD | DDD/1000-PD | DDD/1000-PD | Level Change | Level Change | Level Change | Level Change | Level Change | Level Change | Level Change |
| Targeted Antibiotics | 80.07 | 83.58 | 3.51 | 0.538 |
| Clindamycin | 5.10 | 5.62 | 0.52 | 0.482 |
| Ciprofloxacin | 27.34 | 26.39 | −0.94 | 0.725 |
| Moxifloxacin | 11.96 | 16.98 | 5.02 | 0.013 |
| Metronidazole | 21.26 | 20.59 | −0.66 | 0.482 |
| Vancomycin | 14.41 | 13.98 | −0.42 | 0.817 |
| Control Antibiotics | 102.25 | 110.85 | 8.60 | 0.168 |
| Amoxicillin-clavulanate | 35.34 | 39.68 | 4.34 | 0.236 |
| Ceftriaxone | 42.50 | 41.14 | −1.36 | 0.612 |
| Piperacillin-tazobactam | 24.41 | 30.03 | 5.62 | 0.013 |

**Fig. 2.** Control antibiotic utilization pre and postintervention.
evaluate the accuracy of indication selection nor appropriateness of therapy. However, previous studies have shown high accuracy of selected indication (74%–100%\(^6\)–\(^7\)) for antimicrobials. We infer, based on these studies, that there was moderate to high accuracy and clinical appropriateness in the selection and use of our predefined mandatory indications. This finding was supported by the observations of specific infections noted when the free-text field was used and almost no incomprehensible rationale provided by prescribers.

Our next steps based on our findings include (1) optimizing the predefined list of indications to reflect the most commonly used free-form indications and (2) removing mandatory indications from oral vancomycin and indications pertaining to *Clostridioides difficile* infection from IV and oral metronidazole given the Infectious Diseases Society of America guideline update in 2017.

**Acknowledgments.**

**Financial support.** Funding for statistical support was funded by the Department of Pharmacy, Unity Health Toronto (St. Joseph’s Health Centre site).

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

**References**

1. Fridkin S, Baggs J, Fagan R et al. Vital signs: improving antibiotic use among hospitalized patients. *Morbid Mortal Wkly Rep* 2014;63:194–200.

2. Tamma PD, Avdic E, Li DX et al. Association of adverse events with antibiotic use in hospitalized patients. *JAMA Intern Med* 2017;177:1308–1315.

3. Core elements of hospital antibiotic stewardship programs. Centers for Disease Control and Prevention website. https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf. Published 2020. Accessed July 9, 2020.

4. Nomura Y, Garcia M, Child J, et al. Effect of provider-selected order indications on appropriateness of antimicrobial orders in a pediatric hospital. *Am J Health-Sys Pharm* 2016;73:213–221.

5. Patel JA, Esterly JS, Schetz MH and Postelnick MJ. An analysis of the accuracy of physician-entered indications on computerized antimicrobial orders. *Infect Control Hosp Epidemiol* 2012;33:1066–1067.

6. Timmons V, Townsend J, McKenzie R et al. An evaluation of provider-chosen antibiotic indications as a targeted antimicrobial stewardship intervention. *Am J Infect Control* 2018;46:1174–1179.

7. Heil EL, Pineles L, Mathur P et al. Accuracy of provider-selected indications for antibiotic orders. *Infect Control Hosp Epidemiol* 2018;39:111–113.

8. Wagner AK, Soumerai SD, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time-series studies in medication use research. *J Clin Pharm Therapeut* 2002;27:299–309.

9. Huitema BE, McKean JW. Design specifications issues in time-series intervention models. *Educ Psychol Meas* 2006;66:38–58.

10. Langford BJ, Brown KA, Chan AJ and Downing M. High vs low intensity: What is the optimal approach to prospective audit and feedback in an antimicrobial stewardship program? *Infect Control Hosp Epidemiol* 2019;40(12):1344–1347.

11. Saini S, Leung V, Si E, Ho C et al. Documenting the indication for antimicrobial prescribing: a scoping review. *BMJ Qual Saf* 2022, 1–13.